S100P

Summary

S100P (S100 calcium binding protein P, HGNC:10504) is a protein-coding gene on chromosome 4p16.1, encoding Protein S100-P (P25815). May function as calcium sensor and contribute to cellular calcium signaling.

The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21; however, this gene is located at 4p16. This protein, in addition to binding Ca2+, also binds Zn2+ and Mg2+. This protein may play a role in the etiology of prostate cancer.

Source: NCBI Gene 6286 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 15 total
• Druggable target: yes
• MANE Select transcript: NM_005980

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10504
Approved symbol	S100P
Name	S100 calcium binding protein P
Location	4p16.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000163993
Ensembl biotype	protein_coding
OMIM	600614
Entrez	6286

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000296370, ENST00000513778

RefSeq mRNA: 1 — MANE Select: NM_005980 NM_005980

CCDS: CCDS3391

Canonical transcript exons

ENST00000296370 — 2 exons

Exon	Start	End
ENSE00001080326	6696893	6697170
ENSE00001080327	6693878	6694070

Expression profiles

Bgee: expression breadth ubiquitous, 226 present calls, max score 99.89.

FANTOM5 (CAGE): breadth broad, TPM avg 14.0547 / max 1467.9486, expressed in 515 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46792	13.0289	481
46790	0.6660	189
46791	0.3559	102
46793	0.0039	1

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nasal cavity epithelium	UBERON:0005384	99.89	gold quality
mucosa of urinary bladder	UBERON:0001259	99.67	gold quality
lower esophagus mucosa	UBERON:0035834	99.67	gold quality
palpebral conjunctiva	UBERON:0001812	99.59	gold quality
nasal cavity mucosa	UBERON:0001826	99.59	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.36	gold quality
bone marrow	UBERON:0002371	99.28	gold quality
amniotic fluid	UBERON:0000173	99.25	gold quality
periodontal ligament	UBERON:0008266	99.18	gold quality
epithelium of nasopharynx	UBERON:0001951	99.16	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	99.15	gold quality
pylorus	UBERON:0001166	99.15	gold quality
mucosa of stomach	UBERON:0001199	99.08	gold quality
epithelium of bronchus	UBERON:0002031	98.93	gold quality
bronchus	UBERON:0002185	98.93	gold quality
esophagus squamous epithelium	UBERON:0006920	98.88	gold quality
trabecular bone tissue	UBERON:0002483	98.81	gold quality
pharyngeal mucosa	UBERON:0000355	98.76	gold quality
urethra	UBERON:0000057	98.73	gold quality
rectum	UBERON:0001052	98.71	gold quality
bronchial epithelial cell	CL:0002328	98.70	gold quality
placenta	UBERON:0001987	98.67	gold quality
bone marrow cell	CL:0002092	98.50	gold quality
mucosa of sigmoid colon	UBERON:0004993	98.38	gold quality
trachea	UBERON:0003126	98.31	gold quality
epithelium of esophagus	UBERON:0001976	98.16	gold quality
esophagus mucosa	UBERON:0002469	97.71	gold quality
blood	UBERON:0000178	97.70	gold quality
urinary bladder	UBERON:0001255	97.68	gold quality
buccal mucosa cell	CL:0002336	96.78	gold quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	3016.28
E-MTAB-8410	yes	2634.65
E-MTAB-6701	yes	2616.65
E-HCAD-23	yes	1928.64
E-HCAD-24	yes	1890.91
E-MTAB-10018	yes	1780.06
E-HCAD-15	yes	1584.49
E-ANND-5	yes	753.49
E-GEOD-86618	yes	656.64
E-CURD-11	yes	102.71
E-GEOD-125970	yes	20.50
E-HCAD-10	yes	19.44
E-MTAB-6678	yes	17.91
E-MTAB-9801	yes	10.68
E-MTAB-9067	yes	10.53

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF4, CREB1, NR3C1

miRNA regulators (miRDB)

5 targeting S100P, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-6847-5P	97.93	66.74	1808
HSA-MIR-4257	97.86	68.05	1190
HSA-MIR-6783-5P	97.67	67.21	1528

Literature-anchored findings (GeneRIF, showing 40)

• Data suggest that Bifocal functions downstream of Misshapen to reorganize actin cytoskeleton in decelerating R cell growth cone motility at the target region. (PMID:12467587)
• we show that Misshapen (Msn), the fly homolog of the vertebrate Nck-interacting kinase is a component of a novel signaling pathway that regulates photoreceptor (R-cell) nuclear migration in the developing Drosophila compound eye. (PMID:15582780)
• the lamellocyte-active enhancer in th misshapen gene likely serves as a transcriptional target within a genetic auto-regulatory circuit that promotes the production of lamellocytes in immune-challenged or genetically-compromised animals (PMID:19641625)
• The msn gene functions to modulate the levels and/or distribution of Drosophila E-cadherin to promote the invasive migratory behaviour of border cells. (PMID:21102643)
• Targeted expression of an active form of Msn in the wing imaginal disk disrupted activation of endogenous MAD by Dpp and expression of the Dpp/MAD target gene. (PMID:21690388)
• Misshapen’s conserved role in cell migration and suggest that follicle cell planar polarity may be an emergent property of individual cell migratory behaviors within the epithelium. (PMID:23509067)
• the Misshapen-Warts-Yorkie pathway acts in enteroblasts to control niche signaling to intestinal stem cells (PMID:25453828)
• Results indicate that misshapen (msn) is a key regulator of ovary border cells (BC) migration. (PMID:31477736)
• Misshapen Disruption Cooperates with Ras(V12) to Drive Tumorigenesis. (PMID:33919765)
• characterization of the target-recognition properties of S100P using a model peptide, melittin, support a model for the Ca2+-dependent conformational switch for functional target recognition. (PMID:12021435)
• data suggest that S100P can act in an autocrine manner via RAGE to stimulate cell proliferation and survival (PMID:14617629)
• Results describe the cloning of the 1297 bp full-length cDNA, and the characterization of the tissue-specific expression of the human S100P gene. (PMID:14672411)
• S100P is identified as a novel DNA hypomethylation target in pancreatic neoplasms. (PMID:14716296)
• NMR structure of the Apo-S100P protein (PMID:15213440)
• can be added to the genetic progression model for pancreatic ductal adenocarcinoma. (PMID:15632002)
• results suggest that S100P gene expression is independent of human papillomavirus oncogene protein E7 in cervical carcinoma cell lines and that at least in some cases it is subjected to regulation by DNA methylation (PMID:16047742)
• S100P plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE (PMID:16061848)
• S100P may be an early developmental marker of pancreatic carcinogenesis, and measurement of S100P in pancreatic juice may be useful for early detection of pancreatic cancer or screening of early pancreatic carcinogenesis. (PMID:17000674)
• S100P is upregulated after radical prostatectomy for prostatic neoplasms. (PMID:17448597)
• Hypomethylation of wingless-related MMTV integration site 5A (WNT5A), S100 calcium-binding protein P (S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the cancer cells by bisulfite sequencing. (PMID:17486081)
• High S100P expression in ovarian neoplasms obtained after chemotherapy characterize the worse prognosis. (PMID:17539915)
• Overexpression of S100P leads to increased expression of another early pancreatic cancer marker, S100A6, as well as the aspartic protease cathepsin D, both of which are involved in cellular invasion. (PMID:17875703)
• S100P and pVHL are a pair of sensitive and specific markers for identifying primary pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia (PMID:18162774)
• S100P overexpression upregulated androgen receptor expression and thereby promoted prostate cancer progression by increasing cell growth. Oncogenic nature of S100P in prostate cancer suggests that the protein may directly confer resistance to chemotherapy (PMID:18452169)
• S100P primarily localises in the cytoplasmic and nuclear region as determined for lung adenocarcinoma specimens. (PMID:18575778)
• analysis of the Ca2+ -regulated ezrin-S100P interaction and its role in tumor cell migration (PMID:18725408)
• Expression of the calcium-binding protein S100P is regulated by bone morphogenetic protein in pancreatic duct epithelial cell lines. (PMID:19018761)
• celecoxib up-regulates the expression of S100P through an ATF4-mediated endoplasmic reticulum stress response (PMID:19073601)
• expression of S100P, GATA3, and p63 by a majority of ovarian Brenner tumors underscores the similarity between these neoplasms and urothelial proliferations of bladder origin (PMID:19092634)
• Data show that S100P pa is a novel type of S100 protein mutant locked in a permanently active state that shows an unregulated complex formation with its cellular target ezrin. (PMID:19111582)
• S100P is highly expressed during the implantation window in human endometrium. (PMID:19796763)
• aberrant regulation of S100P in HCC might activate cyclin D1 and CDK expression and contribute to the mitogenic potential of tumor cells during Hepatocellular carcinoma carcinogenesis. (PMID:19885547)
• S100P protein expression is associated with all types of IPMN, from low-grade IPMNs to invasive IPMNs. (PMID:20153506)
• S100P was clearly expressed in the invasive component of intraductal papillary mucinous neoplasms (32/32; 100%), including perineural and lymphatic and minimal invasion. (PMID:20153506)
• Porcupine might contribute to non-small cell lung carcinoma development by ranscriptional activation of cancer-related genes such as s100P. (PMID:20198348)
• The findings of focal S100P and/or IMP3 expression with reciprocal loss of pVHL in a few benign biopsies suggest a use of these markers in the detection of early epithelial dysplasia. (PMID:20382408)
• High S100p is associated with colon cancer. (PMID:20890108)
• The 5-year cumulative survival rate of patients with positive S100P expression was significantly higher than that of patients with negative expression. (PMID:21054985)
• S100P is a novel Ca(2+)-dependent regulator of IQGAP1 that can down-regulate the function of IQGAP1 as a signaling intermediate by direct interaction (PMID:21177863)
• S100P may play an important role in malignant transformation of ductal cells of pleomorphic adenoma (PMID:21317706)

Cross-species orthologs

0 orthologs

Paralogs (21): CRNN (ENSG00000143536), S100A8 (ENSG00000143546), S100A7 (ENSG00000143556), S100B (ENSG00000160307), S100A1 (ENSG00000160678), S100A11 (ENSG00000163191), S100A9 (ENSG00000163220), S100A12 (ENSG00000163221), S100G (ENSG00000169906), S100Z (ENSG00000171643), S100A7A (ENSG00000184330), S100A3 (ENSG00000188015), S100A16 (ENSG00000188643), SNTN (ENSG00000188817), S100A13 (ENSG00000189171), S100A14 (ENSG00000189334), S100A4 (ENSG00000196154), S100A5 (ENSG00000196420), S100A2 (ENSG00000196754), S100A10 (ENSG00000197747), S100A6 (ENSG00000197956)

Protein

Protein identifiers

Protein S100-P — P25815 (reviewed: P25815)

Alternative names: Migration-inducing gene 9 protein, Protein S100-E, S100 calcium-binding protein P

All UniProt accessions (1): P25815

UniProt curated annotations — full annotation on UniProt →

Function. May function as calcium sensor and contribute to cellular calcium signaling. In a calcium-dependent manner, functions by interacting with other proteins, such as EZR and PPP5C, and indirectly plays a role in physiological processes like the formation of microvilli in epithelial cells. May stimulate cell proliferation in an autocrine manner via activation of the receptor for activated glycation end products (RAGE).

Subunit / interactions. Homodimer and heterodimer with S100A1. Interacts with S100PBP and S100Z. Interacts with CACYBP in a calcium-dependent manner. Dimeric form binds to and activates EZR/Ezrin by unmasking its F-actin binding sites. Interacts with PPP5C (via TPR repeats); the interaction is calcium-dependent and modulates PPP5C activity. (Microbial infection) Interacts with P.falciparum (strains 3D7 and FVO) MSP1 subunit p33; the interaction blocks S100P inflammatory and chemotactic activities.

Subcellular location. Nucleus. Cytoplasm. Cell projection. Microvillus membrane.

Tissue specificity. Detected in all of the tissues except brain, testis and small intestine, expression level is higher in placenta, heart, lung, skeletal muscle, spleen and leukocyte. Up-regulated in various pancreatic ductal adenocarcinomas and pancreatic intraepithelial neoplasias.

Miscellaneous. This protein binds two calcium ions.

Similarity. Belongs to the S-100 family.

RefSeq proteins (1): NP_005971* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001751	S100/CaBP7/8-like_CS	Conserved_site
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR013787	S100_Ca-bd_sub	Domain
IPR034325	S-100_dom	Domain

Pfam: PF01023

UniProt features (26 total): binding site 8, helix 5, mutagenesis site 4, sequence conflict 3, strand 3, domain 2, chain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
1J55	X-RAY DIFFRACTION	2
7NMI	X-RAY DIFFRACTION	2.1
1OZO	SOLUTION NMR
2MJW	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P25815-F1	87.24	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 73; 25; 27; 32; 62; 64; 66; 68

Mutagenesis-validated functional residues (4):

Position	Phenotype
21–23	in s100ppa; permanently active, interacts with ezr and ppp5c in absence of calcium; when associated with c-64, k-68 and
64	in s100ppa; permanently active, interacts with ezr and ppp5c in absence of calcium; when associated with 21-s–g-23, k-6
68	in s100ppa; permanently active, interacts with ezr and ppp5c in absence of calcium; when associated with 21-s–g-23, c-6
73	in s100ppa; permanently active, interacts with ezr and ppp5c in absence of calcium; when associated with 21-s–g-23, c-6

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 248 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, KOBAYASHI_EGFR_SIGNALING_24HR_UP, REACTOME_INNATE_IMMUNE_SYSTEM, JAEGER_METASTASIS_DN, GOCC_SECRETORY_GRANULE, MODULE_45, MODULE_16, PATIL_LIVER_CANCER, MODULE_118, KANG_FLUOROURACIL_RESISTANCE_DN, MISSIAGLIA_REGULATED_BY_METHYLATION_UP, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, HUPER_BREAST_BASAL_VS_LUMINAL_UP

GO Biological Process (1): endothelial cell migration (GO:0043542)

GO Molecular Function (9): magnesium ion binding (GO:0000287), calcium ion binding (GO:0005509), protein homodimerization activity (GO:0042803), cadherin binding (GO:0045296), transition metal ion binding (GO:0046914), calcium-dependent protein binding (GO:0048306), protein binding (GO:0005515), identical protein binding (GO:0042802), metal ion binding (GO:0046872)

GO Cellular Component (10): extracellular region (GO:0005576), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), microvillus membrane (GO:0031528), secretory granule lumen (GO:0034774), extracellular exosome (GO:0070062), plasma membrane (GO:0005886), membrane (GO:0016020), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Innate Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
metal ion binding	3
protein binding	2
cell migration	1
identical protein binding	1
protein dimerization activity	1
cell adhesion molecule binding	1
calcium ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
microvillus	1
cell projection membrane	1
secretory granule	1
cytoplasmic vesicle lumen	1
extracellular vesicle	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1391 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
S100P	S100PBP	Q96BU1	982
S100P	ATAD1	Q8NBU5	514
S100P	OAZ1	P54368	448
S100P	SAT1	P21673	422
S100P	KRTAP17-1	Q9BYP8	336
S100P	ADCYAP1	P18509	325
S100P	BTNL2	Q9UIR0	321
S100P	S100A13	Q99584	314
S100P	S100A14	Q9HCY8	311
S100P	KCNV2	Q8TDN2	305
S100P	IQGAP1	P46940	300
S100P	NDUFAF6	Q330K2	298
S100P	DUSP1	P28562	293
S100P	CRIP1	P50238	291
S100P	S100A7	P31151	272

IntAct

115 interactions, top by confidence:

A	B	Type	Score
TP53	TP53	psi-mi:“MI:0915”(physical association)	0.980
S100P	S100A1	psi-mi:“MI:0915”(physical association)	0.880
S100A1	S100P	psi-mi:“MI:0915”(physical association)	0.880
S100A1	S100P	psi-mi:“MI:0407”(direct interaction)	0.880
S100P	S100A1	psi-mi:“MI:0403”(colocalization)	0.880
S100P	S100A1	psi-mi:“MI:2364”(proximity)	0.880
S100P	S100B	psi-mi:“MI:0915”(physical association)	0.780
S100B	S100P	psi-mi:“MI:0915”(physical association)	0.780
S100B	S100P	psi-mi:“MI:0914”(association)	0.780
MYH9	S100P	psi-mi:“MI:0407”(direct interaction)	0.680
S100P	MYH9	psi-mi:“MI:0407”(direct interaction)	0.680
MYH9	S100P	psi-mi:“MI:0915”(physical association)	0.680
S100P	NEFL	psi-mi:“MI:0915”(physical association)	0.670
CCNC	MED19	psi-mi:“MI:0914”(association)	0.640
TFIP11	S100P	psi-mi:“MI:0915”(physical association)	0.560
S100P	TFIP11	psi-mi:“MI:0915”(physical association)	0.560
S100P	S100A1	psi-mi:“MI:0915”(physical association)	0.560
S100A1	S100P	psi-mi:“MI:0915”(physical association)	0.560
IL11	S100P	psi-mi:“MI:0407”(direct interaction)	0.560
	IL11	psi-mi:“MI:0407”(direct interaction)	0.560

BioGRID (304): S100P (Two-hybrid), TFIP11 (Two-hybrid), S100P (Affinity Capture-MS), S100P (Two-hybrid), S100P (Reconstituted Complex), S100P (Affinity Capture-MS), S100P (Two-hybrid), S100P (Proximity Label-MS), S100P (Affinity Capture-MS), S100P (Affinity Capture-MS), S100P (Affinity Capture-MS), S100P (Affinity Capture-MS), S100P (Affinity Capture-MS), S100P (Affinity Capture-MS), S100A1 (Two-hybrid)

ESM2 similar proteins: O77691, O77791, P02638, P02639, P04271, P04354, P04467, P04631, P05937, P05942, P05964, P06702, P06703, P07091, P07171, P10462, P12658, P14069, P23297, P24479, P25815, P26447, P27004, P28318, P29034, P30801, P31151, P35466, P35467, P50114, P56565, P79105, P79880, P80310, P80511, P97352, Q0VCM0, Q14ST5, Q28050, Q2EN75

Diamond homologs: A7K6Y9, O77691, O77791, P02632, P02633, P02634, P02638, P02639, P04271, P04631, P05942, P05964, P06702, P06703, P07091, P10462, P14069, P20930, P23297, P24480, P25815, P26447, P27003, P28318, P28783, P29034, P29377, P30801, P33763, P33764, P35466, P35467, P50114, P50116, P50117, P56565, P62818, P62819, P63083, P63084

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
STUB1	“down-regulates quantity by destabilization”	S100P	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

15 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	14
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

180 predictions. Top by Δscore:

Variant	Effect	Δscore
4:6696887:CTCTA:C	acceptor_loss	1.0000
4:6696888:TCTA:T	acceptor_loss	1.0000
4:6696890:TA:T	acceptor_loss	1.0000
4:6696891:A:AG	acceptor_gain	1.0000
4:6696891:AGAGT:A	acceptor_gain	1.0000
4:6696892:G:GG	acceptor_gain	1.0000
4:6696892:GA:G	acceptor_gain	1.0000
4:6696892:GAGTG:G	acceptor_gain	1.0000
4:6694071:G:GA	donor_loss	0.9900
4:6694072:T:A	donor_loss	0.9900
4:6696890:TAG:T	acceptor_gain	0.9900
4:6696891:AGA:A	acceptor_gain	0.9900
4:6696892:G:C	acceptor_gain	0.9900
4:6696892:GAGT:G	acceptor_gain	0.9900
4:6696888:TCTAG:T	acceptor_gain	0.9800
4:6696889:CTAG:C	acceptor_gain	0.9800
4:6694067:GCAG:G	donor_gain	0.9600
4:6694071:G:GG	donor_gain	0.9600
4:6696291:G:GT	donor_gain	0.9400
4:6696195:G:GG	donor_gain	0.8700
4:6695243:GGC:G	donor_gain	0.8400
4:6695244:GCG:G	donor_gain	0.8400
4:6696194:A:AG	donor_gain	0.8400
4:6694036:TGCTG:T	donor_gain	0.8200
4:6696224:GCTC:G	donor_gain	0.7700
4:6695288:A:G	donor_gain	0.7500
4:6696200:A:T	donor_gain	0.7500
4:6694073:G:GT	donor_loss	0.7300
4:6694249:C:T	donor_gain	0.6900
4:6696199:G:GT	donor_gain	0.6900

AlphaMissense

627 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:6693975:T:C	F15L	0.994
4:6693977:T:A	F15L	0.994
4:6693977:T:G	F15L	0.994
4:6696974:T:C	F74L	0.993
4:6696976:C:A	F74L	0.993
4:6696976:C:G	F74L	0.993
4:6696965:T:C	F71L	0.989
4:6696967:C:A	F71L	0.989
4:6696967:C:G	F71L	0.989
4:6693951:G:C	A7P	0.985
4:6694030:T:C	L33P	0.982
4:6696975:T:C	F74S	0.981
4:6696990:C:A	A79D	0.980
4:6693952:C:A	A7D	0.975
4:6696992:G:C	A80P	0.975
4:6694039:T:C	L36P	0.972
4:6697001:T:C	S83P	0.971
4:6693976:T:C	F15S	0.970
4:6694030:T:A	L33H	0.969
4:6694054:T:C	L41P	0.969
4:6696939:A:T	D62V	0.969
4:6696972:A:T	E73V	0.968
4:6694015:T:C	L28P	0.967
4:6696966:T:C	F71S	0.967
4:6696989:G:C	A79P	0.966
4:6694015:T:A	L28Q	0.965
4:6696938:G:C	D62H	0.965
4:6696999:C:A	T82K	0.964
4:6696940:C:A	D62E	0.963
4:6696940:C:G	D62E	0.963

dbSNP variants (sampled 300 via entrez): RS10009150 (4:6692083 A>G), RS1001060511 (4:6694253 G>A,T), RS1001085607 (4:6692967 T>C), RS10019431 (4:6692171 G>A), RS10019716 (4:6692436 G>A), RS1002064918 (4:6695564 T>C), RS1002414154 (4:6693516 C>T), RS1002747774 (4:6694541 G>C), RS1003120082 (4:6696379 G>C), RS1003843249 (4:6692676 G>A), RS1003898770 (4:6692407 G>C), RS1004877183 (4:6694855 C>T), RS1004902744 (4:6693534 G>A), RS1005271936 (4:6696016 C>A), RS1005850682 (4:6694881 A>G)

Disease associations

OMIM: gene MIM:600614 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001762_114	Obesity-related traits	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005109	energy expenditure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066932 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.23	Kd	583.4	nM	CHEMBL5653589
6.23	ED50	583.4	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149334: Binding affinity to human S100P incubated for 45 mins by Kinobead based pull down assay	kd	0.5834	uM

CTD chemical–gene interactions

150 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, increases expression, decreases expression	6
Benzo(a)pyrene	increases methylation, decreases reaction, affects cotreatment, increases expression, decreases expression	5
Cyclosporine	increases expression	4
Decitabine	affects expression, decreases expression, decreases reaction, increases expression	3
Cisplatin	affects cotreatment, increases expression, increases response to substance	3
Tobacco Smoke Pollution	affects expression, increases expression	3
Paclitaxel	increases response to substance, decreases expression	3
arsenite	affects binding, increases reaction, decreases methylation, increases expression	2
cotylenin A	increases expression	2
Oxaliplatin	decreases expression, increases response to substance	2
Acetaminophen	decreases expression	2
Cadmium	decreases methylation, increases expression	2
Copper	increases expression, affects binding, decreases expression	2
Cyclophosphamide	decreases expression, affects response to substance	2
Etoposide	affects response to substance, increases response to substance	2
Fluorouracil	decreases expression, affects response to substance, increases response to substance	2
Hydrogen Peroxide	affects expression, increases expression	2
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, decreases expression	2
Tretinoin	increases expression	2
Valproic Acid	increases expression, increases methylation	2
Medroxyprogesterone Acetate	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
fluxapyroxad	increases expression	1
3,19-(2-bromobenzylidene)andrographolide	increases expression, decreases response to substance	1
ethoprop	increases expression	1
N(6)-(delta(2)-isopentenyl)adenine	increases expression	1
tungsten carbide	affects cotreatment, decreases expression	1
tremortin	increases expression	1
methylmercuric chloride	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652376	Binding	Binding affinity to human S100P incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2EJ	Abcam HeLa S100P KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.